undamentalytics Newsletter
Sign in

Cerenome, Inc. cash flow statement

In fiscal 2025, Cerenome, Inc.'s operations generated −$20.8m of cash; it spent $67,000 on capital projects, leaving free cash flow of −$20.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−24−24−35−32−35−30−20−20−18−12−13−11−21−22
Depreciation and amortisation21112111221100
Stock-based pay33344321101123
Capital spending01111110000001
Free cash flow−24−24−36−33−35−31−21−20−18−12−13−11−21−24
Free cash flow after stock pay−27−27−39−37−39−34−23−21−19−12−14−11−22−27
Share buybacks——————————00——
Shares issued23451325181929212406723—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CNSY vs INBSBMRA vs CNSYCNSY vs MCTACNSY vs ICCM

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Cerenome, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cerenome, Inc.